Robert Lafyatis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6892430/publications.pdf

Version: 2024-02-01

167 papers	12,719 citations	22153 59 h-index	29157 104 g-index
176 all docs	176 docs citations	176 times ranked	14266 citing authors

#	Article	IF	Citations
1	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet, The, 2016, 387, 2630-2640.	13.7	505
2	Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 54, 1802441.	6.7	400
3	Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunity, 2020, 52, 183-199.e9.	14.3	383
4	Generation of Transgene-Free Lung Disease-Specific Human Induced Pluripotent Stem Cells Using a Single Excisable Lentiviral Stem Cell Cassette Â. Stem Cells, 2010, 28, 1728-1740.	3.2	375
5	Partial Inhibition of Integrin Î±vÎ²6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 56-65.	5.6	371
6	Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis. New England Journal of Medicine, 2014, 370, 433-443.	27.0	365
7	Shared and distinct mechanisms of fibrosis. Nature Reviews Rheumatology, 2019, 15, 705-730.	8.0	331
8	Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion. Nature Immunology, 2019, 20, 724-735.	14.5	297
9	A macrophage marker, siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type i interferons and toll-like receptor agonists. Arthritis and Rheumatism, 2007, 56, 1010-1020.	6.7	280
10	Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. Journal of Clinical Investigation, 2015, 125, 2795-2807.	8.2	271
11	Transforming growth factor Î²â€”at the centre of systemic sclerosis. Nature Reviews Rheumatology, 2014, 10, 706-719.	8.0	253
12	B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis and Rheumatism, 2009, 60, 578-583.	6.7	250
13	Toll-Like Receptor 4 Signaling Augments Transforming Growth Factor-Î² Responses. American Journal of Pathology, 2013, 182, 192-205.	3.8	243
14	SFRP2/DPP4 and FMO1/LSP1 Define Major Fibroblast Populations in Human Skin. Journal of Investigative Dermatology, 2018, 138, 802-810.	0.7	236
15	Tenascin-C drives persistence of organ fibrosis. Nature Communications, 2016, 7, 11703.	12.8	204
16	Integrated Single-Cell Atlas of Endothelial Cells of the Human Lung. Circulation, 2021, 144, 286-302.	1.6	181
17	Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: A novel mouse model for scleroderma?. Arthritis and Rheumatism, 2011, 63, 1707-1717.	6.7	178
18	Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease. Annals of the Rheumatic Diseases, 2019, 78, 1379-1387.	0.9	178

#	Article	IF	Citations
19	Association of Interferonâ€•and Transforming Growth Factor Î²â€“Regulated Genes and Macrophage Activation With Systemic Sclerosisâ€“Related Progressive Lung Fibrosis. Arthritis and Rheumatology, 2014, 66, 714-725.	5.6	169
20	Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?. PLoS ONE, 2008, 3, e1452.	2.5	164
21	Interleukin-1 Stimulates andAll-Trans-Retinoic Acid Inhibits Collagenase Gene Expression through Its 5â€² Activator Protein-1-Binding Site. Molecular Endocrinology, 1990, 4, 973-980.	3.7	161
22	Increased Frequency and Compromised Function of T Regulatory Cells in Systemic Sclerosis (SSc) Is Related to a Diminished CD69 and TGFÎ² Expression. PLoS ONE, 2009, 4, e5981.	2.5	159
23	The Pronounced Th17 Profile in Systemic Sclerosis (SSc) Together with Intracellular Expression of TGFÎ² and IFNÎ³ Distinguishes SSc Phenotypes. PLoS ONE, 2009, 4, e5903.	2.5	158
24	Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis. Journal of Investigative Dermatology, 2013, 133, 1979-1989.	0.7	150
25	B cell infiltration in systemic sclerosisâ€“associated interstitial lung disease. Arthritis and Rheumatism, 2007, 56, 3167-3168.	6.7	148
26	B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nature Communications, 2021, 12, 3349.	12.8	142
27	Antimalarial agents: Closing the gate on toll-like receptors?. Arthritis and Rheumatism, 2006, 54, 3068-3070.	6.7	139
28	Intrinsic Gene Expression Subsets of Diffuse Cutaneous Systemic Sclerosis Are Stable in Serial Skin Biopsies. Journal of Investigative Dermatology, 2012, 132, 1363-1373.	0.7	138
29	Limited Systemic Sclerosis Patients with Pulmonary Arterial Hypertension Show Biomarkers of Inflammation and Vascular Injury. PLoS ONE, 2010, 5, e12106.	2.5	133
30	Stability of a PKCI-1-related mRNA is controlled by the splicing factor ASF/SF2: a novel function for SR proteins. Genes and Development, 2002, 16, 594-607.	5.9	128
31	Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis and Rheumatism, 2011, 63, 1718-1728.	6.7	125
32	Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2827-2830.	7.1	122
33	Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 1362-1371.	0.9	122
34	Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Research and Therapy, 2007, 9, S4.	3.5	121
35	Poly(I:C) Drives Type I IFN- and TGFÎ²-Mediated Inflammation and Dermal Fibrosis Simulating Altered Gene Expression in Systemic Sclerosis. Journal of Investigative Dermatology, 2010, 130, 2583-2593.	0.7	121
36	Increased Expression of Wnt2 and SFRP4 in Tsk Mouse Skin: Role of Wnt Signaling in Altered Dermal Fibrillin Deposition and Systemic Sclerosis. Journal of Investigative Dermatology, 2008, 128, 871-881.	0.7	114

#	Article	IF	Citations
37	Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. Journal of Clinical Investigation, 2020, 130, 2451-2464.	8.2	106
38	Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nature Communications, 2021, 12, 7338.	12.8	104
39	Tau exon 10, whose missplicing causes frontotemporal dementia, is regulated by an intricate interplay of cis elements and trans factors. Journal of Neurochemistry, 2004, 88, 1078-1090.	3.9	102
40	Myofibroblast transcriptome indicates SFRP2hi fibroblast progenitors in systemic sclerosis skin. Nature Communications, 2021, 12, 4384.	12.8	101
41	Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis and Rheumatism, 2006, 54, 3655-3660.	6.7	100
42	miR-155 in the progression of lung fibrosis in systemic sclerosis. Arthritis Research and Therapy, 2016, 18, 155.	3.5	96
43	A Longitudinal Biomarker for the Extent of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2015, 67, 3004-3015.	5.6	95
44	Epsteinâ€“Barr Virus Infection Induces Aberrant TLR Activation Pathway and Fibroblastâ€“Myofibroblast Conversion in Scleroderma. Journal of Investigative Dermatology, 2014, 134, 954-964.	0.7	89
45	Sustained Î²â€catenin activity in dermal fibroblasts promotes fibrosis by upâ€regulating expression of extracellular matrix proteinâ€coding genes. Journal of Pathology, 2015, 235, 686-697.	4.5	89
46	Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity, 2019, 51, 548-560.e4.	14.3	88
47	Regulation of the transforming growth factor-Î²1 and -Î²3 promoters by transcription factor Spl. Gene, 1993, 129, 223-228.	2.2	87
48	p300 Is Elevated in Systemic Sclerosis and Its Expression Is Positively Regulated by TGF-Î²: Epigenetic Feed-Forward Amplification of Fibrosis. Journal of Investigative Dermatology, 2013, 133, 1302-1310.	0.7	87
49	Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors. Clinical Cancer Research, 2019, 25, 4443-4454.	7.0	87
50	Complex Regulation of Tau Exon 10, Whose Missplicing Causes Frontotemporal Dementia. Journal of Neurochemistry, 2001, 74, 490-500.	3.9	80
51	Interspecies Comparison of Human and Murine Scleroderma Reveals IL-13 and CCL2 as Disease Subset-Specific Targets. American Journal of Pathology, 2012, 180, 1080-1094.	3.8	78
52	A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis. PLoS ONE, 2015, 10, e0126015.	2.5	77
53	An Autotaxin/Lysophosphatidic Acid/Interleukinâ€6 Amplification Loop Drives Scleroderma Fibrosis. Arthritis and Rheumatology, 2016, 68, 2964-2974.	5.6	76
54	GDF15 is an epithelial-derived biomarker of idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L510-L521.	2.9	72

#	Article	IF	Citations
55	Tau Exons 2 and 10, Which Are Misregulated in Neurodegenerative Diseases, Are Partly Regulated by Silencers Which Bind a SRp30cÂ·SRp55 Complex That Either Recruits or Antagonizes htra2Î²1. Journal of Biological Chemistry, 2005, 280, 14230-14239.	3.4	69
56	Innate immunity and inflammation in systemic sclerosis. Current Opinion in Rheumatology, 2009, 21, 617-622.	4.3	69
57	Cloning by Polymerase Chain Reaction of a New Mouse TGF-Î², mTGF-Î²3. Growth Factors, 1990, 3, 139-146.	1.7	68
58	DIMM-SC: a Dirichlet mixture model for clustering droplet-based single cell transcriptomic data. Bioinformatics, 2018, 34, 139-146.	4.1	68
59	Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placeboâ€Controlled Trial in Adults With Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1350-1360.	5.6	67
60	Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis. Arthritis Research and Therapy, 2014, 16, R136.	3.5	65
61	Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-15.	1.7	64
62	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. Transplantation and Cellular Therapy, 2021, 27, 817-835.	1.2	62
63	SF2 and SRp55 regulation of CD45 exon 4 skipping during T cell activation. European Journal of Immunology, 1999, 29, 823-837.	2.9	59
64	Transforming growth factor ? induces fibroblast fibrillin-1 matrix formation. Arthritis and Rheumatism, 2002, 46, 3000-3009.	6.7	59
65	Identification of Cadherin 11 as a Mediator of Dermal Fibrosis and Possible Role in Systemic Sclerosis. Arthritis and Rheumatology, 2014, 66, 1010-1021.	5.6	59
66	Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor Î± and interleukin-1. Arthritis and Rheumatism, 1993, 36, 772-780.	6.7	56
67	A Bayesian mixture model for clustering droplet-based single-cell transcriptomic data from population studies. Nature Communications, 2019, 10, 1649.	12.8	56
68	Increased Expression of Endoplasmic Reticulum Stress and Unfolded Protein Response Genes in Peripheral Blood Mononuclear Cells From Patients With Limited Cutaneous Systemic Sclerosis and Pulmonary Arterial Hypertension. Arthritis and Rheumatism, 2013, 65, 1357-1366.	6.7	54
69	Skin-Resident Effector Memory CD8+CD28â€“ T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis. Journal of Investigative Dermatology, 2017, 137, 1042-1050.	0.7	54
70	Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease. Frontiers in Immunology, 2021, 12, 595811.	4.8	54
71	Mutant fibrillin 1 from tight skin mice increases extracellular matrix incorporation of microfibril-associated glycoprotein 2 and type I collagen. Arthritis and Rheumatism, 2004, 50, 915-926.	6.7	53
72	Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin. Frontiers in Immunology, 2018, 9, 2191.	4.8	53

#	Article	IF	Citations
73	Long noncoding RNA H19X is a key mediator of TGF-Î²â€“driven fibrosis. Journal of Clinical Investigation, 2020, 130, 4888-4905.	8.2	52
74	Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Research and Therapy, 2007, 9, 222.	3.5	51
75	The c-Abl tyrosine kinase controls protein kinase CÎ´-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis and Rheumatism, 2011, 63, 1729-1737.	6.7	50
76	Thymic Stromal Lymphopoietin Is Upâ€Regulated in the Skin of Patients With Systemic Sclerosis and Induces Profibrotic Genes and Intracellular Signaling That Overlap With Those Induced by Interleukinâ€13 and Transforming Growth Factor Î². Arthritis and Rheumatism, 2013, 65, 1335-1346.	6.7	50
77	Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin. Annals of the Rheumatic Diseases, 2014, 73, 1864-1872.	0.9	50
78	The Mammalian Homolog of Suppressor-of-white-apricot Regulates Alternative mRNA Splicing of CD45 Exon 4 and Fibronectin IIICS. Journal of Biological Chemistry, 1996, 271, 31106-31114.	3.4	49
79	Microfibril-associated MAGP-2 Stimulates Elastic Fiber Assembly. Journal of Biological Chemistry, 2007, 282, 800-808.	3.4	48
80	Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90. American Journal of Pathology, 2016, 186, 2650-2664.	3.8	48
81	Antagonistic Effect of the Matricellular Signaling Protein CCN3 on TGF-Î²- and Wnt-Mediated Fibrillinogenesis in Systemic Sclerosis and Marfan Syndrome. Journal of Investigative Dermatology, 2010, 130, 1514-1523.	0.7	47
82	Single-cell RNA sequencing profiling of mouse endothelial cells in response to pulmonary arterial hypertension. Cardiovascular Research, 2022, 118, 2519-2534.	3.8	45
83	A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin. Journal of Investigative Dermatology, 2017, 137, 62-70.	0.7	44
84	Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 912-919.	5.6	44
85	Transcriptome landscape of myeloid cells in human skin reveals diversity, rare populations and putative DC progenitors. Journal of Dermatological Science, 2020, 97, 41-49.	1.9	44
86	Inhibition of Î²-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82. Journal of Investigative Dermatology, 2017, 137, 2473-2483.	0.7	43
87	Transforming Growth Factor-? in Rheumatoid Arthritis. Annals of the New York Academy of Sciences, 1990, 593, 197-207.	3.8	40
88	Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of SystemicÂSclerosis. Journal of Investigative Dermatology, 2017, 137, 1671-1681.	0.7	39
89	Expansion of FcÎ³ Receptor <scp>IIIa</scp>â€“Positive Macrophages, Ficolin 1â€“Positive <scp>MonocyteâEDerived</scp> Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis. Arthritis and Rheumatology, 2022, 74, 329-341.	5.6	38
90	Frataxin deficiency promotes endothelial senescence in pulmonary hypertension. Journal of Clinical Investigation, 2021, 131, .	8.2	38

#	Article	IF	Citations
91	Dendritic cells maintain dermal adiposeâ€“derived stromal cells in skin fibrosis. Journal of Clinical Investigation, 2016, 126, 4331-4345.	8.2	38
92	New Insights into the Mechanisms of Innate Immune Receptor Signalling in Fibrosis. Open Rheumatology Journal, 2012, 6, 72-79.	0.2	38
93	Endothelial cells and the pathogenesis of rheumatoid arthritis in humans and streptococcal cell wall arthritis in Lewis rats. Journal of Cellular Biochemistry, 1991, 45, 162-166.	2.6	37
94	Sequence specific protein binding to and activation of the TGF-Î²3 promoter through a repeated TCCC motif. Nucleic Acids Research, 1991, 19, 6419-6425.	14.5	37
95	High Rhodotorula Sequences in Skin Transcriptome of Patients with Diffuse Systemic Sclerosis. Journal of Investigative Dermatology, 2014, 134, 2138-2145.	0.7	37
96	Role of aggrecanase 1 in Lyme arthritis. Arthritis and Rheumatism, 2006, 54, 3319-3329.	6.7	36
97	Skewed X chromosomal inactivation impacts T regulatory cell function in systemic sclerosis. Annals of the Rheumatic Diseases, 2010, 69, 2213-2216.	0.9	36
98	Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model. Arthritis and Rheumatology, 2015, 67, 3146-3157.	5.6	36
99	Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. International Journal of Molecular Medicine, 2012, 30, 1473-1480.	4.0	35
100	Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics. Arthritis and Rheumatology, 2016, 68, 2003-2015.	5.6	35
101	dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts. Annals of the Rheumatic Diseases, 2011, 70, 544-550.	0.9	33
102	Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis. Annals of the Rheumatic Diseases, 2021, 80, 1453-1460.	0.9	32
103	Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3. Nature Immunology, 2022, 23, 868-877.	14.5	32
104	Fibrillin in Marfan syndrome and tight skin mice provides new insights into transforming growth factor-Î² regulation and systemic sclerosis. Current Opinion in Rheumatology, 2006, 18, 582-587.	4.3	29
105	The cytokine language of monocytes and macrophages in systemic sclerosis. Arthritis Research and Therapy, 2010, 12, 146.	3.5	29
106	The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. Rheumatology, 2016, 55, 911-917.	1.9	29
107	Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity. Nature Communications, 2021, 12, 4314.	12.8	29
108	Increased expression of type I collagen induced by microfibril-associated glycoprotein 2: Novel mechanistic insights into the molecular basis of dermal fibrosis in scleroderma. Arthritis and Rheumatism, 2005, 52, 1812-1823.	6.7	28

#	Article	IF	Citations
109	Modulation of the membrane-binding projection domain of tau protein: splicing regulation of exon 3. Molecular Brain Research, 2002, 101, 109-121.	2.3	27
110	Toll interacting protein protects bronchial epithelial cells from bleomycinâ€induced apoptosis. FASEB Journal, 2020, 34, 9884-9898.	0.5	27
111	Type I Interferons Inhibition of Inflammatory T Helper Cell Responses in Systemic Lupus Erythematosus. Annals of the New York Academy of Sciences, 2007, 1108, 11-23.	3.8	26
112	Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors <scp>PD</scp>â€1, <scp>TIGIT</scp>, and <scp>TIM</scp>â€3 in Lymphocytes From Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 566-577.	5.6	26
113	Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis. Science Translational Medicine, 2020, 12, .	12.4	26
114	Fibulin-2 and Fibulin-5 Alterations in Tsk Mice Associated with Disorganized Hypodermal Elastic Fibers and Skin Tethering. Journal of Investigative Dermatology, 2004, 123, 1063-1069.	0.7	24
115	Resolution of Skin Fibrosis by Neutralization of the Antifibrinolytic Function of Plasminogen Activator Inhibitor 1. Arthritis and Rheumatology, 2016, 68, 473-483.	5.6	23
116	Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1374-1380.	0.9	23
117	Anti-CD95-induced Lethality Requires Radioresistant FcÎ³RII+ Cells. Journal of Biological Chemistry, 2003, 278, 7553-7557.	3.4	22
118	Targeting Fibrosis in Systemic Sclerosis. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2006, 6, 395-400.	1.2	22
119	Perivascular Adventitial Fibroblast Specialization Accompanies T Cell Retention in the Inflamed Human Dermis. Journal of Immunology, 2019, 202, 56-68.	0.8	22
120	TRPV4 ION Channel Is Associated withÂScleroderma. Journal of Investigative Dermatology, 2017, 137, 962-965.	0.7	21
121	A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. Arthritis Research and Therapy, 2019, 21, 202.	3.5	21
122	Single-cell transcriptome conservation in a comparative analysis of fresh and cryopreserved human skin tissue: pilot in localized scleroderma. Arthritis Research and Therapy, 2020, 22, 263.	3.5	21
123	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clinical Reviews in Allergy and Immunology, 2023, 64, 239-261.	6.5	20
124	HLA-B35 and dsRNA Induce Endothelin-1 via Activation of ATF4 in Human Microvascular Endothelial Cells. PLoS ONE, 2013, 8, e56123.	2.5	20
125	Xerostomia in Systemic Sclerosis: Systematic Evaluation by Salivary Scintigraphy and Lip Biopsy in Thirty-Four Patients. Arthritis and Rheumatism, 1994, 37, 439-441.	6.7	19
126	Single cell RNA sequencing identifies IGFBP5 and QKI as ciliated epithelial cell genes associated with severe COPD. Respiratory Research, 2021, 22, 100.	3.6	18

#	Article	IF	Citations
127	Modulation of tissue resident memory T cells by glucocorticoids after acute cellular rejection in lung transplantation. Journal of Experimental Medicine, 2022, 219, .	8.5	18
128	The state of differentiation of HT-29 colon carcinoma cells alters the secretion of cathepsin D and of plasminogen activator. International Journal of Cancer, 1994, 57, 875-882.	5.1	17
129	Acid sphingomyelinase deficiency contributes to resistance of scleroderma fibroblasts to Fas-mediated apoptosis. Journal of Dermatological Science, 2012, 67, 166-172.	1.9	16
130	Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis. Arthritis Research and Therapy, 2016, 18, 27.	3.5	16
131	Increased dermal collagen bundle alignment in systemic sclerosis is associated with a cell migration signature and role of Arhgdib in directed fibroblast migration on aligned ECMs. PLoS ONE, 2017, 12, e0180751.	2.5	16
132	The HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients. Arthritis Research and Therapy, 2015, 17, 363.	3.5	15
133	Local skin gene expression reflects both local and systemic skin disease in patients with systemic sclerosis. Rheumatology, 2016, 55, 377-379.	1.9	14
134	Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature. Arthritis Research and Therapy, 2017, 19, 156.	3.5	14
135	Stretching Reduces Skin Thickness and Improves Subcutaneous Tissue Mobility in a Murine Model of Systemic Sclerosis. Frontiers in Immunology, 2017, 8, 124.	4.8	13
136	Cigarette smoke exposure enhances transforming acidic coiled-coilâ€“containing protein 2 turnover and thereby promotes emphysema. JCI Insight, 2020, 5, .	5.0	13
137	KIAA0317 regulates pulmonary inflammation through SOCS2 degradation. JCI Insight, 2019, 4, .	5.0	13
138	Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 146-149.	0.8	13
139	SScâ€”fibrosis takes flight with Wingless inhibition. Nature Reviews Rheumatology, 2012, 8, 441-442.	8.0	12
140	Application of Biomarkers to Clinical Trials in Systemic Sclerosis. Current Rheumatology Reports, 2012, 14, 47-55.	4.7	12
141	Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. Journal of Scleroderma and Related Disorders, 2018, 3, 242-248.	1.7	12
142	Mitochondria, Aging, and Cellular Senescence: Implications for Scleroderma. Current Rheumatology Reports, 2020, 22, 37.	4.7	12
143	Kelch-like protein 42 is a profibrotic ubiquitin E3 ligase involved in systemic sclerosis. Journal of Biological Chemistry, 2020, 295, 4171-4180.	3.4	12
144	Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. Rheumatology, 2021, 60, 4662-4670.	1.9	12

#	Article	IF	Citations
145	Analytic Review: Care of Patients With Scleroderma in the Intensive Care Setting. Journal of Intensive Care Medicine, 2010, 25, 247-258.	2.8	10
146	Role for tollâ€like receptor 3 in muscle regeneration after cardiotoxin injury. Muscle and Nerve, 2011, 43, 733-740.	2.2	10
147	Elevated expression of cavâ€1 in a subset of <scp>SS</scp>c fibroblasts contributes to constitutive Alk1/Smad1 activation. Journal of Cellular and Molecular Medicine, 2012, 16, 2238-2246.	3.6	10
148	Skin Fibrosis and Recovery Is Dependent on Wnt Activation via DPP4. Journal of Investigative Dermatology, 2022, 142, 1597-1606.e9.	0.7	10
149	The -2518A>G promoter polymorphism in the CCL2 gene is not associated with systemic sclerosis susceptibility or phenotype: Results from a multicenter study of European Caucasian patients. Human Immunology, 2009, 70, 130-133.	2.4	9
150	Reduced Proportion and Activity of Natural Killer Cells in the Lung of Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 608-610.	5.6	9
151	IL4RA on lymphatic endothelial cells promotes T cell egress during sclerodermatous graft versus host disease. JCI Insight, 2016, 1, .	5.0	8
152	Pristane-Accelerated Autoimmune Disease in (SWR X NZB) F1 Mice Leads to Prominent Tubulointerstitial Inflammation and Human Lupus Nephritis-Like Fibrosis. PLoS ONE, 2016, 11, e0164423.	2.5	7
153	Antibodies in raheumatoid synovial fluids bind to a restricted series of protein antigens in rheumatoid synovial tissue. Arthritis and Rheumatism, 1992, 35, 1016-1027.	6.7	6
154	Editorial: Epigenetics in Systemic Sclerosis. Arthritis and Rheumatology, 2016, 68, 2841-2844.	5.6	6
155	Rituximab: a potential therapeutic advance in scleroderma: What is the evidence?. Rheumatology, 2010, 49, 201-202.	1.9	5
156	A pilot study of dimethyl fumarate in pulmonary arterial hypertension associated with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2021, 6, 242-246.	1.7	5
157	Î²-Agonist exposure preferentially impacts lung macrophage cyclic AMP-related gene expression in asthma and asthma COPD overlap syndrome. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L837-L843.	2.9	5
158	Single-Cell Analyses of Human Pancreas: Characteristics of two populations of acinar cells in chronic pancreatitis. American Journal of Physiology - Renal Physiology, 2021, 321, G449-G460.	3.4	5
159	Progress and Priorities in Systemic Sclerosis: The Next 10 Years â€“ Report from the World Scleroderma Foundation. Journal of Scleroderma and Related Disorders, 2016, 1, 7-9.	1.7	3
160	SF2 and SRp55 regulation of CD45 exon 4 skipping during T cell activation. European Journal of Immunology, 1999, 29, 823-837.	2.9	3
161	Etiology and pathogenesis of systemic sclerosis. , 2015, , 1177-1189.		3
162	Overview of Animal Models. , 2012, , 291-307.		1

#	Article	IF	Citations
163	Expression cloning using antibodies from a patient with rheumatoid arthritis of an autoantigen homologous to the Drosophila splicing regulator, suppressor-of-white-apricot. , 1994, , 59-73.		1
164	Disease Classification Using Molecular Signatures. , 2012, , 71-81.		0
165	Modeling Innate Immunity in Murine Skin: Utilization of Subcutaneous Osmotic Pumps for Inflammatory and Fibrotic Skin Disease. Methods in Molecular Biology, 2012, 900, 317-326.	0.9	0
166	Increased expression of ER stress genes in patients with limited cutaneous Systemic Sclerosis and Pulmonary Arterial Hypertension. FASEB Journal, 2013, 27, 1166.11.	0.5	0
167	Biomarkers in Systemic Sclerosis. , 2017, , 245-260.		0